Literature DB >> 6993778

Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading.

A Helber, G Wambach, W Hummerich, G Bönner, K A Meurer, W Kaufmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993778     DOI: 10.1007/bf01476798

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


× No keyword cloud information.
  27 in total

Review 1.  Low-renin ("primary") hyperaldosteronism. Differential diagnosis and distinction of sub-groups within the syndrome.

Authors:  J B Ferriss; D G Beevers; J J Brown; R Fraser; A F Lever; P L Padfield; J I Robertson
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

2.  Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension.

Authors:  M L Tuck; G H Williams; J P Cain; J M Sullivan; R G Dluhy
Journal:  Am J Cardiol       Date:  1973-10       Impact factor: 2.778

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  [Radioimmunoassay for urinary aldosterone. Aldosterone excretion in essential hypertensives (author's transl)].

Authors:  A Helber; W Kaufmann
Journal:  Klin Wochenschr       Date:  1973-12-01

5.  Low renin hypertension: a state of inappropriate secretion of aldosterone.

Authors:  C E Grim; T J Peters; J F Maher
Journal:  J Lab Clin Med       Date:  1971-11

6.  Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess.

Authors:  R F Spark; J C Melby
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

7.  Effect of an adrenal inhibitor in hypertensive patients with suppressed renin.

Authors:  J W Woods; G W Liddle; A M Michelakis; A B Brill
Journal:  Arch Intern Med       Date:  1969-04

8.  Salivary sodium-potassium ratio and plasma renin activity in hypertension.

Authors:  V Adlin; B J Channick; A D Marks
Journal:  Circulation       Date:  1969-05       Impact factor: 29.690

9.  Clinical, biochemical and pathological features of low-renin ("primary") hyperaldosteronism.

Authors:  J B Ferriss; D G Beevers; J J Brown; D L Davies; R Fraser; A F Lever; P Mason; A M Neville; J I Robertson
Journal:  Am Heart J       Date:  1978-03       Impact factor: 4.749

10.  Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity.

Authors:  R D Collins; M H Weinberger; A J Dowdy; G W Nokes; C M Gonzales; J A Luetscher
Journal:  J Clin Invest       Date:  1970-07       Impact factor: 14.808

View more
  7 in total

1.  Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.

Authors:  P O Lim; R T Jung; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Primary aldosteronism and salt.

Authors:  John W Funder
Journal:  Pflugers Arch       Date:  2014-12-13       Impact factor: 3.657

Review 3.  Progress in primary aldosteronism: present challenges and perspectives.

Authors:  C E Gomez-Sanchez; G P Rossi; F Fallo; M Mannelli
Journal:  Horm Metab Res       Date:  2010-01-20       Impact factor: 2.936

4.  Cardiovascular and adrenal sensitivity to angiotensin II in essential hypertension.

Authors:  G Wambach; U Meiners; G Bönner; A Konrads; A Helber
Journal:  Klin Wochenschr       Date:  1984-12-03

5.  Plasma levels of atrial natriuretic peptide are raised in essential hypertension during low and high sodium intake.

Authors:  G Wambach; S Götz; G Suckau; G Bönner; W Kaufmann
Journal:  Klin Wochenschr       Date:  1987-03-02

6.  The Potential of ACTH in the Genesis of Primary Aldosteronism.

Authors:  John W Funder
Journal:  Front Endocrinol (Lausanne)       Date:  2016-05-23       Impact factor: 5.555

Review 7.  Spironolactone in cardiovascular disease: an expanding universe?

Authors:  John W Funder
Journal:  F1000Res       Date:  2017-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.